GSK

Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Elegen is a biotechnology company founded in 2017 and led by Dr. Matthew Hill, specializing in the development of microfluidic technology. The company focuses on creating innovative DNA synthesizers that enhance the engineering of entire genomes. By leveraging its advanced technology, Elegen aims to accelerate biomedical advancements and facilitate DNA sequence testing within the healthcare industry. Through its commitment to disrupting synthetic biology, Elegen is positioned to play a pivotal role in the future of genetic research and applications.

BioVersys AG is a biopharmaceutical company based in Basel, specializing in the research and development of innovative therapies aimed at addressing multidrug-resistant bacterial infections. The company is dedicated to combating the growing global health challenge posed by bacterial drug resistance, which severely limits the effectiveness of current antibiotics. BioVersys employs its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to identify new treatments by targeting and inhibiting the mechanisms that confer resistance to bacterial pathogens. This approach not only enhances the efficacy of existing antibiotics but also provides healthcare professionals with new therapeutic options to treat life-threatening infections.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Patientory Inc., established in 2015 and headquartered in Atlanta, Georgia, specializes in developing a personal healthcare solution named Patientory. This platform enables individuals to securely manage their medical records, monitor chronic illnesses, and access relevant health information. Simultaneously, it facilitates healthcare providers' connection with patients for support and care coordination. By empowering users to control their health data and incentivizing healthier lifestyles through personalized rewards, Patientory aims to streamline interactions between healthcare stakeholders and patients while reducing care costs.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

Cadherx Therapeutics develops therapeutic antibodies targeting soluble E-cadherin.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

SpringLeaf Therapeutics (formerly known as Entra Pharmaceuticals, Inc.) is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on convergent science and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Flybridge Capital Partners and North Bridge Venture Partners.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of innovative diagnostic products with significant clinical relevance. The company's flagship product, the PLAC Test, assesses levels of Lp-PLA2, an enzyme linked to the formation of harmful plaque in blood vessels, which is a key factor in cardiovascular events like heart disease and stroke. The PLAC Test is unique as it is the only FDA-cleared blood test that aids in evaluating the risk for coronary heart disease and ischemic stroke related to atherosclerosis. In addition to cardiovascular diagnostics, diaDexus offers test kits for various conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with a growing presence in Europe and other regions worldwide.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

It is a joint venture company

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of innovative diagnostic products with significant clinical relevance. The company's flagship product, the PLAC Test, assesses levels of Lp-PLA2, an enzyme linked to the formation of harmful plaque in blood vessels, which is a key factor in cardiovascular events like heart disease and stroke. The PLAC Test is unique as it is the only FDA-cleared blood test that aids in evaluating the risk for coronary heart disease and ischemic stroke related to atherosclerosis. In addition to cardiovascular diagnostics, diaDexus offers test kits for various conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with a growing presence in Europe and other regions worldwide.

Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.